HEALTH TECHNOLOGY

Philips and IJsselland Hospital sign long-term technology partnership

Royal Philips | December 24, 2021

Royal Philips, a global leader in health technology, today announced it has signed a 12-year strategic partnership with IJsselland Hospital (Capelle aan den Ijssel, The Netherlands). As the hospital’s strategic technology partner, Philips will target improved care for patients and care providers at IJsselland Hospital and in the surrounding region. The collaboration will focus on innovation, digitalization and optimization, and includes the purchase of patient monitoring and radiology solutions including CT and MRI systems.

Home monitoring collaboration expanded
In addition to the new strategic partnership, Philips and IJsselland Hospital plan to expand their existing home monitoring partnership for patients with heart failure and COPD. Philips will provide clinical and patient decision support software which enables implementation of remote health and care programs and facilitates collaboration between different healthcare providers.

“Technological developments in healthcare are currently moving very fast,” said Albert van Wijk, Chairman of IJsselland Hospital’s Board of Directors. “As a regional hospital, we want to keep up with these developments to provide the best care for our patients. We have chosen Philips as a technology partner to jointly develop the hospital of the future. This will be good for our patients and our healthcare professionals. Moreover, Philips’ vision fits well with our strategy.”

“Over the past year, we have worked with IJsselland Hospital to convert their strategy and challenges into a partnership. I am very proud of this partnership, in which we don’t focus solely on technology but look more broadly at the challenges the hospital faces. A great deal of attention is paid to innovation, which is why we are starting a joint fund for innovation and optimization. We also want to work explicitly on optimizing care processes, so that the hospital can work smarter and save costs.”

Léon Kempeneers, Health Systems, Philips Benelux

About Royal Philips

Royal Philips is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. 

Spotlight

Amid a looming shortage of experienced RNs, hospitals are spending billions on creative strategies to attract and keep qualified staff. At the same time, the nursing industry has one of the highest turnover rates—especially among new hires, according to a new infographic by nurse grad. The infographic examines the factors contributing to the expected shortage and how an effective recruitment and retention strategy can help health systems succeed in this environment.

Spotlight

Amid a looming shortage of experienced RNs, hospitals are spending billions on creative strategies to attract and keep qualified staff. At the same time, the nursing industry has one of the highest turnover rates—especially among new hires, according to a new infographic by nurse grad. The infographic examines the factors contributing to the expected shortage and how an effective recruitment and retention strategy can help health systems succeed in this environment.

Related News

FUTURE OF HEALTHCARE

Veritas Capital Completes Combination of Coronis Health and MiraMed Global Services

Veritas Capital | August 08, 2022

Veritas Capital a leading technology and government investor with deep healthcare expertise, announced that an affiliate of Veritas completed the combination of two complementary revenue cycle management businesses: Coronis Health and MiraMed Global Services. The combination creates a scaled RCM platform providing end-to-end technology-enabled solutions to a diverse set of healthcare providers across the U.S. The newly combined company benefits from meaningfully increased scale, end-to-end RCM capabilities across multiple specialties, and robust infrastructure with over 8,500 employees globally. The combined company will be led by Coronis CEO Stephen Grubbs. MiraMed’s founder and CEO Tony Mira will serve as Vice Chairman of the Board of Directors. Veritas has a proven track record of driving growth for companies within the healthcare technology market. The firm brings a culture of intense customer focus and accelerating growth through investment in R&D and product innovation. Coronis is a leading provider of end-to-end RCM solutions to U.S. healthcare providers including primary and specialty physician practices, anesthesia groups, laboratories, emergency medical services, behavioral health centers, FQHCs, and hospitals. Since its founding in 2015, Coronis has rapidly become an industry leader with an emphasis on quality, transparency, and customer satisfaction. Coronis’ solutions address the full RCM continuum for a patient’s journey, allowing clients to focus on delivering high quality patient care to communities they serve. Veritas acquired Coronis from 424 Capital and other minority shareholders. Founded by Tony and Sue Mira in 1979, MiraMed is a leading provider of end-to-end RCM and business process outsourcing services for anesthesia practices and commercial healthcare clients in the U.S. MiraMed delivers medical coding, billing, and receivables management solutions to regional anesthesia-focused physician practices and other commercial healthcare clients, supported by a highly strategic hybrid onshore/offshore delivery model. Veritas acquired MiraMed from the Mira family, who will retain an ownership position in the combined company. “This combination brings together two highly complementary businesses with a shared mission to improve operations for healthcare providers across the U.S. Coronis’ end-to-end RCM solutions paired with MiraMed’s expertise and global infrastructure creates a robust platform for growth in a highly fragmented market. We look forward to leveraging our expertise in healthcare technology to support the combined company and, in partnership with management, deliver innovative technology-based solutions to ensure the continued success of the company’s healthcare provider clients.” Ramzi Musallam, CEO and Managing Partner of Veritas Capital “We are thrilled to partner with Veritas Capital through this combination, which will better position us to help our clients focus on providing what’s most important – the absolute best patient care,” said Mr. Grubbs, CEO of Coronis. “MiraMed has a terrific team and value proposition, and we are confident that, with a larger platform and enhanced resources provided by Veritas, the combined company is poised for continued organic and inorganic growth to benefit our clients, employees, and partners." “Our family built MiraMed to serve the growing needs of our healthcare clients and their patients. By combining with Coronis, we created a new company with the scale, resources, and global infrastructure to provide an expanded set of solutions to our clients,” said Tony Mira, founder and CEO of MiraMed. “Together, we will expand our operational footprint to serve clients across various specialties and make investments in technology to enhance operations for our clients across the healthcare industry. I look forward to working with the talented team at Coronis, as well as Veritas, as we embark on this next chapter.” “Our investment in Coronis and partnership with Stephen and the entire management team firmly established how our playbook can create value in the healthcare technology sector,” said 424 Capital Managing Partner Walter Beinecke. “We welcome Veritas as the new stewards of Coronis and wish the team continued success.” Latham & Watkins LLP served as legal counsel to Veritas. Lincoln International LLC and TripleTree LLC served as financial advisors to Veritas. Guggenheim Securities LLC served as lead financial advisor and Whiteman Osterman & Hanna LLP served as legal counsel to Coronis. Gibson, Dunn & Crutcher LLP served as legal counsel to MiraMed. About Veritas Capital Veritas is a longstanding technology investor with a focus on companies operating at the intersection of technology and government. The firm invests in companies that provide critical products, software, and services, primarily technology and technology-enabled solutions, to government and commercial customers worldwide. Veritas seeks to create value by strategically transforming the companies in which it invests through organic and inorganic means. Leveraging technology to make a positive impact across vitally important areas, such as healthcare, education, and national security, is core to Veritas. We are proud stewards of national assets, improving the quality of healthcare while reducing cost, advancing our educational system, and protecting our nation and allies. About Coronis Health Coronis is a leading provider of end-to-end RCM solutions to U.S. healthcare providers including primary and specialty physician practices, laboratories, and hospitals. By using industry-leading technology combined with high-touch relationship building, Coronis Health allows healthcare practitioners to focus on patient care. About MiraMed Global Services MiraMed is a leading provider of end-to-end RCM and Business Process Outsourcing services for anesthesia practices and commercial healthcare clients in the U.S. MiraMed partners with physician practices, hospitals, health networks, and related industry service organizations to provide a broad portfolio of solutions to streamline operations, improve productivity and ensure compliance.

Read More

HEALTH TECHNOLOGY

Francisco Partners Launches Data Company Merative After Acquiring IBM’s Healthcare Data and Analytics Assets

Francisco Partners and Merative | July 01, 2022

The acquisition of the healthcare data and analytics assets that were a part of IBM's Watson Health business, has been completed, according to Francisco Partners, a renowned international investment firm that specializes in working with technology companies. The new standalone business, which will be owned by Francisco Partners, will be known as Merative and have its headquarters in Ann Arbor, Michigan. Merative serves clients in the life sciences, provider, imaging, health plan, employer, and government health and human services sectors by bringing together market-leading offerings that give value across the global healthcare ecosystem. “Merative has market leading products, top clients and talented leadership. With the commitment, support and deep experience of Francisco Partners, we will invest heavily in expanding the reach of these products as we continue to work with clients to improve healthcare delivery, decision making and performance.” Gerry McCarthy Paul Roma, General Manager of the Watson Health business, is slated to transition to the role of Senior Advisor to Francisco Partners. “Paul has been instrumental in driving crucial transformation of the business. His relentless focus on customers has laid a solid foundation to build on, and we thank him for his leadership,” said McCarthy.

Read More

HEALTH TECHNOLOGY

ZetrOZ Systems Highlights the Rise in Health Insurance Denials, Provides Solution

ZetrOZ Systems | May 30, 2022

ZetrOZ Systems, leaders in wearable medical technology and makers of the sam® wearable ultrasound device that heals soft tissue, highlighted the rising health insurance claim denials. The organization is encouraging customers to inform themselves about their healthcare policies and challenge the first denial. Millions of people in the U.S. have experienced the devastating denial of their healthcare claims. According to Change Healthcare, 11% of 102 million medical claims at 1,500 hospitals are denied at first. The rate of denials has gone up by 20% since the year 2016. "Unfortunately, medical policies are driven by insurance company profits and fear of change. Thus, patients are often denied advanced new care when they need to access their healthcare benefits for soft tissue injuries." George K. Lewis, Ph.D. and CEO of ZetrOZ Systems "The first 'no' by an insurance policy can be turned into a 'yes' if you are informed and persistent," Lewis continued. "At ZetrOZ, we encourage patients and providers to not simply give up with the first denial of an insurance claim for therapies like Sustained Acoustic Medicine (sam®). Your insurance should always cover treatments that are proven to be both medically effective and cost-effective." If a denial letter is received, consumers can appeal against the decision. Possible issues include inaccurate paperwork, incorrect billing code, misplaced tax ID or wrongly coding the prescription or procedure. Inspite of sam®’s success, it is usually not covered by the first line of treatment. The reason is often an inadequate understanding of the costs and care by patients, insurers, and insurance providers.

Read More